Condition: Esophageal Squamous Cell Carcinoma · Esophageal Neoplasms · Esophageal Diseases · Sponsor: Jiangxi Provincial Cancer Hospital
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma (ESCC) Patients as Postoperative Adjuvant Therapy. In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with TQB2450 Injection in treatment of patients with ESCC. The primary endpoint is disease free survival (DFS).
This description comes directly from the study's public registry record.
Changying Guo, PhD · 0086-079188313179 · guochangying0809@163.com
Weimin Mao, PhD · maowm1318@163.com
Always discuss trial participation with your own doctor first.
| Jiangxi Cancer Hospital | Nanchang, Jiangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05252078